The Biden administration recently warned that Medicare could spend $3.5 billion on a new category of Alzheimer's drugs in 2025 alone – a figure vastly higher than what experts in the field predict – leading many to question the math.
Marvell Adams Jr.
Advertisement
Articles by Marvell Adams Jr.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
Baxter reports 5% revenue growth in Q3 as new CEO launches improvement effort
2
1 in 10 people report gluten sensitivity without celiac disease; Eli Lilly, Walmart partner to offer retail access to Zepbound; early-onset cancer and the workplace – Morning Medical Update
3
The psychology of needle phobia: Why it’s a bigger health challenge than we think
4
AI, malpractice and the future of physician liability
5
